Repost by UtopiaSilver.com; by Elliot Overton; Dr. Derrick Lonsdale, a true luminary in the field of nutritional medicine, passed away last year at the ripe old age of 100 years old. Beginning his career as a pediatrician at the Cleveland clinic, he dedicated nearly five decades to uncovering the profound impact of high-dose thiamine (vitamin B1) on chronic disease. He was a vocal proponent of the orthomolecular approach to medicine, and tirelessly sought to raise awareness of what he referred to as high-calorie malnutrition-a state where an abundance of processed foods depletes essential micronutrients, impairing metabolism at a fundamental level and setting the stage for chronic health conditions.
Furthermore, his pioneering work challenged conventional medicine's narrow view of vitamin deficiency, revealing that pharmacological doses of thiamine may achieve far more than merely prevent deficiency-they can actively restore energy metabolism. Dr. Lonsdale often referred to this nutrient as the "spark of life" and "gateway to energy metabolism," emphasising its vital role in counteracting the metabolic stressors of modern life when administered in appropriate amount. He introduced the concept of thiamine dependency-the state where some individuals require supraphysiological doses on a consistent basis to maintain health-an insight that may be highly relevant to many modern chronic diseases. Remarkably, much of what he hypothesized decades ago is now being validated by cutting edge research, demonstrating that his intuitive sense was accurate.
Yet, despite his extensive research and clinical contributions, thiamine remains one of the most overlooked nutrients in medicine today. Even after seven years of applying these principles, I am still astounded by the transformative effects this vitamin can have in such a broad range of health problems.
In the sections that follow, we will explore thiamine's essential role in bioenergetics, its unique anti-stress properties, and the overlooked concept of organ-specific localized deficiency-an emerging phenomenon that may be crucial for specific health conditions, particularly neurodegenerative disease. We will also examine the rationale behind using pharmacological doses as a powerful therapeutic intervention for a wide array of modern diseases.
Thiamine: A Universal "Anti-Stress" Molecule
Thiamine (also known as vitamin B1) is an essential vitamin naturally found in a variety of whole foods, especially meats and organs, legumes and whole grains. Due to its hydrophilic nature and short half-life, it requires continuous dietary replenishment. Its widespread role in human physiology centres on its participation as an essential cofactor for enzymes involved in various biochemical pathways. Among these, thiamine-dependent dehydrogenases are uniquely positioned at key metabolic cross-points, enabling cellular metabolic flexibility and modulating the global rate of energy metabolism. Pyruvate Dehydrogenase (PDH), the rate-limiting enzyme for mitochondrial glucose oxidation, bridges glycolysis and the TCA cycle, rendering thiamine indispensable for efficient utilization of carbohydrate. Alpha-Ketoglutarate Dehydrogenase (KGDH), another rate-limiting enzyme of the TCA cycle, links bioenergetics, amino acid metabolism, and neurotransmitter synthesis. Beyond the generation of NADH and disposal of glutamate, KGDH acts as a metabolic "signaling hub," influencing redox balance, growth, the hypoxic response, protein signaling, and calcium homeostasis (1).
The unique positioning of these rate-limiting thiamine-dependent enzymes at critical junctures in metabolism means that they are tasked with governing the global rate of ATP production. For this reason, intracellular thiamine levels are also tightly coupled to mitochondrial oxygen utilization. Insufficient thiamine levels disrupt this process, leading to pseudohypoxia-a state in which cells cannot utilize oxygen despite adequate availability, leading to widespread energy deficit.
This connection is evidenced by the striking resemblance between the histological changes observed in thiamine-deficient brains and those seen in hypoxic injury (2-4). Both conditions activate the same coordinated cellular response to stress, marked by the stabilization and activation of Hypoxia-Inducible Factor 1-alpha (HIF-1α) (5-7). Additionally, both hypoxia and thiamine deficiency were shown to upregulate SLC19A3, a membrane-bound thiamine transporter, presumably as a compensatory mechanism to enhance thiamine uptake into the cell for the purpose of stress mitigation. Consistent with these findings, a decline in thiamine status correlates with hypothermia and and a marked reduction in oxidative metabolic rate in animals (8). Furthermore, in was shown to produce identical symptoms those found in Hans Selye's model of "The General Adaptation Syndrome" (9). Reflecting this tight-knit relationship between thiamine, bioenergetics, and adaptation to stress, Dr. Lonsdale aptly referred to thiamine as "the spark of life" and "the gateway to energy metabolism."
Thiamine's anti-stress properties also appear to be conserved across plants, fungi, and bacteria. The nutrient has been referred to as an "environmental stress protectant" and "stress alarmone" (10) in plants. Under conditions of biotic and abiotic stress, plants are known to increase their production of thiamine and upregulate thiamine-dependent enzymes as a means of improving resilience in the face of unfavorable environmental conditions. Furthermore, exogenous thiamine confers resistance against many different types of disease (11).
https://www.sciencedirect.com/science/article/abs/pii/B9780123864796000044
For bacteria, similar upregulation of genes involved in thiamine biosynthesis occurs in cyanobacteria under stress (12), and E. coli were found to "accumulate large amounts of thiamine triphosphate, a thiamine derivative, under severe energy stress (13). In yeast, thiamine also confers protection against oxidative, osmotic, and thermal stress (14).
From a broad perspective, it would appear that thiamine exhibits distinctive "anti-stress" properties and can enhance cellular resilience across diverse biological systems. Recognizing these qualities can provide a solid foundation for understanding how and why thiamine might be so useful in mitigating the impact of chronic health conditions which are characterized by metabolic, oxidative, and environmental stressors.
"The Great Imitator": The Many Faces of Deficiency
A severe deficiency in this nutrient is classically know to result in thiamine deficiency disorders (TDDs), which predominantly affect one or more of three major body systems: The central nervous system (causing Wernicke encephalopathy), the cardiovascular system (causing Wet Beriberi), and the peripheral nerves (leading to Dry Beriberi). The classic pattern of symptoms depends on the subtype and can include, but is not limited to, ataxia, opthalmoplegia, peripheral neuropathy, paresthesia, vertigo, vascular insufficiency, edema, and even heart failure. However, micronutrient status should best be understood as existing on a continuum, rather than as a clear-cut binary divide between 'sufficiency' and 'deficiency.' The latter view is overly simplistic and fails to capture the complex and progressive effects that insufficiency can exert on human physiology. Evidence shows that even marginal deficits in thiamine can manifest in subtle yet significant ways, negatively impacting metabolism and organ function long before overt deficiency disorders are diagnosed. Given the ubiquity of thiamine-dependent enzymes and their governing role in energy metabolism, it is conceivable that sufficiency and/or impaired utilization of thiamine could therefore impact any cell, tissue and organ which requires ATP. Indeed, nearly a century's worth of research has demonstrated that even mild insufficiency can manifest in a broad array of non-specific symptoms that extent well beyond the classic spectrum of TDDs. Given thiamine's central role in energy metabolism, organs with the highest demand for energy are the most vulnerable, with many associated symptoms reflecting some degree of autonomic dysfunction. Lonsdale himself spearheaded the treatment of dysautonomia (of various kinds) with thiamine derivatives (15-17), based on the principle that it could address disturbed bioenergetics in the limbic/brainstem regions of the brain involved in modulation of the autonomic nervous system. In his own words: "Beriberi is the prototype for functional dysautonomia in its early stages." (16). He described the brain as becoming "hyper-irritable" under oxidative stress, leading to exaggerated autonomic nervous system responses to even minor stimuli, such as changes in weather or exposure to air conditioning. Indeed, signs and symptoms of dysautonomia are remarkably prevalent among all of the established TDDs (18-21), and in my own experience, thiamine can be the single most effective treatment for such conditions. Clinical manifestations range from mild to severe, and can also fluctuate based on season, physical activity level, and other environmental factors. Furthermore, they can be non-specific and therefore difficult to pinpoint in clinical practice. The general and non-specific nature of symptoms was illustrated as early as 1940 in one of the first ever studies on experimental deficiency in human subjects (22). Remarkably, classical signs of beriberi were virtually absent for the majority of the study period (88 days). Instead, the researchers documented a broad range of symptoms pertaining to every body system, many of which fall under the modern diagnostic umbrella of dysautonomia. These symptoms included: Fatigue upon mild exertion, tachycardia, pseudoangina, irregular heart rate, pallor, blushing, hyperhidrosis, temperature dysregulation, genitourinary paresthesia, frequency of micturition, shortness of breath, vertigo, impaired glucose tolerance, insomnia, along with mood disturbances and poor concentration. General malaise, heavy sensation in the lower extremities, loss of strength, chest tightness, diminished visual acuity and restlessness. Abdominal distension, belching, and alternating constipation and diarrhea, achlorhydria or hypochlorhydria, delayed gastric emptying, and reduced intestinal motility. These broad and often nebulous symptoms observed in thiamine insufficiency highlight the challenges involved in accurate identification, and no doubt contributes to its misdiagnosis. Many of these manifestations are subtle, easily overlooked, and commonly misattributed to other conditions, which leads to widespread under recognition. In reality, thiamine insufficiency develops insidiously, raising an important question: Could a significant portion of the population be affected without realizing it?Thiamine Insufficiency: A Hidden Epidemic
Outside of the context of specific comorbidities such as alcoholism (23), malabsorptive syndromes (24), and eating disorders (25), frank deficiency widely considered rare in developed nations, with the prevailing assumption that food fortification has largely eradicated it. A closer examination of the evidence, however, suggests otherwise.
Insufficiency is, in fact, far more prevalent than commonly recognized (26), with some studies showing occurrence between 20-50% in psychiatric (27) and elderly populations (28,29). Plasma thiamine levels were up to 76% lower in type 1 and type 2 diabetics (30). Even severe cases of Wernicke Encephalopathy are frequently underdiagnosed (31). Furthermore, testing methods are woefully inadequate for assessing intracellular thiamine status (32).
Perhaps the primary driver of widespread deficiency is the occurrence of "high-calorie malnutrition", a term popularized by Lonsdale describing the overconsumption of processed foods rich in calories but devoid of micronutrients, which progressively depletes the body's reserves. This is especially relevant in the modern world, given that consumption of ultra-processed foods has risen substantially in recent decades (33) and now accounts for 50-60% daily caloric intake in some high-income countries (34).
Thiamine status is largely influenced by carbohydrate intake, which necessitates a proportional dietary supply to match metabolic demands (35). In other words, the overconsumption of sugar-laden foods and refined starches naturally places a large burden on the body's thiamine reserves. One of the most striking examples of thiamine's importance comes from the historical epidemic of beriberi in Asia, where populations who were reliant on polished white rice (devoid of thiamine-rich husks) were the first to suffer from severe deficiency.
However, another insidious driver is the widespread consumption of oxidized, PUFA-rich industrial seed oils, as demonstrated by a recent study effect (36). Although the exact mechanism wasn't elucidated, research suggests that oxidized breakdown products of PUFAs, such as malondialdehyde, can negatively impact thiamine status in several ways (37,38). Additionally, there are many pharmaceutical drugs which also display potent anti-thiamine effects, such as metformin (39), metronidazole (40), diuretics (41), and omeprazole (42) among several others (43). Dysbiotic changes to the gut microbiome (44), along with stressors of various kinds can also be responsible for reducing thiamine status (45).
However, the complexity of this issue extends beyond simple deficiency. In fact, a significant portion of patients who present with thiamine-responsive health conditions may not even have insufficient systemic levels of thiamine. That is, despite "normal" circulating thiamine levels, functional impairment at the cellular or enzymatic level may still justify supplementation with high doses. This emerging area of research, which I find particularly fascinating, challenges the conventional paradigms of nutritional status and highlights the need for more nuanced understanding of nutrient handling and nutritional therapy as a whole.
Beyond Addressing Deficiency: Localized or Functional Impairments in Thiamine Utilization
Dr. Derrick Lonsdale often emphasized that high-dose thiamine functions as a pharmacological agent rather than merely a nutritional supplement. The doses required to achieve therapeutic effects-often hundreds or even thousands of times the Recommended Dietary Allowance (RDA)-far exceed what is needed to correct a simple nutritional deficiency, and for prolonged periods of time. In his own words, high-dose thiamine could "coerce energy metabolism back to life," acting as a metabolic stimulant of sorts.The Pharmacological Action of Thiamine
This concept is perhaps best illustrated in examples of inborn errors of metabolism, such as thiamine-responsive maple syrup urine disease, Leigh's disease, methylmalonic academia, homocysteinuria, and other hereditary vitamin-responsive disorders. In these conditions, genetic mutations reduce the affinity of vitamin-dependent enzymes for their respective vitamin cofactor, leading to severe metabolic dysfunction. Mega-doses of the nutrient are required to saturate cells, and compensate for these enzymatic defects, effectively restoring function despite the genetic abnormality (46). While rare, I suspect that similar principles may apply to a much broader range of modern diseases involving enzymatic inactivation or inhibition of vitamin-dependent pathways. This inactivation can occur independently of genetic predisposition and may result from environmental toxins, xenobiotics, chronic inflammation, or oxidative stress. In the context of thiamine-responsive conditions, the issue is not a simple deficiency of thiamine intake but rather defective intracellular handling of thiamine or a functional blockade of thiamine-dependent enzymes, which happen to be uniquely sensitive to such insults (47). There are numerous factors unrelated to dietary intake that have this effect, including:- Heavy metals (e.g., aluminum, arsenic) (48,49)
- Neuroinflammatory molecules (50)
- Mycotoxins (51)
- Pro-oxidants (52)
- Xenobiotics (53)
Localized "Deficiency" in Specific Organs & Tissues
The inhibition or "blockade" of thiamine-dependent, rate-limiting enzymes of involved in energy metabolism can mimic the consequences of a systemic nutritional deficiency, but may instead be restricted to specific tissues. Emerging evidence supports the concept of localized thiamine deficiency various tissues and organs, including the brain, heart, pancreas, and even intestine. For this reason, thiamine can be considered a metabolic stimulant, as high-dose administration has the capacity to restore energy metabolism when cells become saturated, via bypassing or overriding metabolic blocks imposed by enzymatic inhibition. In essence, this perspective shifts the focus beyond from merely correcting dietary deficiency to addressing localized dysfunction and enzyme inhibition, potentially offering new therapeutic possibilities for a wide range of chronic conditions. Another important consideration is that tissues with high metabolic demand -particularly in the context of chronic injury or infection- can rapidly deplete their thiamine reserves in response to stress. Such is another scenario that can potentially lead to localized deficiency, in the absence of systemic signs, symptoms, and/or diagnostic tests. Transcriptomic data (forthcoming publication) supports this notion, revealing distinct metabolic abnormalities, including long-term alterations thiamine-dependent enzymes, in enterocytes up to 9 months after gastric bypass surgery. It is conceivable that such changes could occur in practically any cell, tissue or organ exposed to chronic injury, and should therefore be considered in our approach to managing chronic illness. Furthermore, genetic factors undoubtedly play an important role. Abnormalities in genes encoding proteins involved in the transport, activation, and utilization of thiamine could render an individual more susceptible even to minor fluctuations in thiamine status. Such genetic differences may also help to account for some individuals respond favorably to this therapy, while others do not.Keys to Neurodegeneration: Untapped potential for the aging brain?
These mechanisms are particularly relevant in the field of neurodegeneration, where decades of research highlight a strong link between disrupted thiamine homeostasis and neurodegenerative processes. Notably, dysfunction of thiamine-dependent enzymes appears to be a hallmark feature of several neurodegenerative conditions, suggesting that localized thiamine dysfunction may be a key contributor to CNS vulnerability and disease progression.Alzheimer's Dementia (AD)
A "localized deficiency" of thiamine in the brain has been proposed as a defining characteristic of AD (56), and is known to independently cause many of the key pathological changes including: impaired glucose metabolism (57), neuroinflammation (58), neuron loss (59), impaired cholinergic function (60) and greater presence of amyloid plaques and tangles (61). Disruptions of cerebral thiamine homeostasis and glucose metabolism have been identified (62), and activity of three thiamine-dependent enzymes are reduced in the brain (63,64). One of those is KGDH, whose activity is reduced by as much as 57% (65,66) which occurs in both genetic (67) and sporadic (68) forms of AD. Furthermore, Thiamine transporters decline (69) and metabolic impairments in the brain are closely related to TPP levels (70). Furthermore, levels of active TPP were significantly reduced in the frontal, temporal, parietal and occipital cortex in frontotemporal dementia (71) at autopsy. The synthetic thiamine derivative benfotiamine has been shown to counteract many of the pathological drivers of AD and cognitive decline (72), and a $45 milllon trial is currently underway in AD patients (73).Parkinson's Disease
Endogenous neurotoxic metabolites associated with PD, such as MPP+ and isoquinolones, are potent inhibitors of thiamine-dependent enzymes (74), Numerous studies have identified KGDH as a key pathological target in Parkinson's disease (PD) (75). KGDH activity is greatly reduced in the substantia nigra (76), with the degree of inhibition correlating with the severity of neurodegeneration (77). Additionally, PD is associated with significant reductions in PDH activity (78,79). Free thiamine concentrations in cerebrospinal fluid were also found to be lower than controls (80). Although there are only two small trials using pharmacological doses of thiamine for PD, the results are extremely promising (81,82). In one of those reports, patients with a milder phenotype achieved complete clinical remission with thiamine therapy. Today, there is an online network of thousands who are self-treating with this approach and are witnessing great benefits. According to the author of the case reports: "It is reasonable to infer that a focal, severe thiamine deficiency due to a dysfunction of thiamine metabolism could cause selective neuronal damage in the centres that are typically hit in this disease. Injection of high doses of thiamine was effective in reversing the symptoms, suggesting that the abnormalities in thiamine-dependent processes could be overcome by diffusion-mediated transport at supranormal thiamine concentrations."The Cholinergic System
Although widespread deficits to the cholinergic system are a well-recognized pathological hallmark of AD, similar -or even more severe- deficits may also occur in PD, albeit in different regions of the brain (83,84). These shared mechanisms may help to further shed light on why thiamine holds significant therapeutic potential. Thiamine is inherently pro-cholinergic, playing a crucial role in acetylcholine (ACh) function at multiple levels. An intimate relationship between thiamine and cholinergic neurotransmission stems from both its coenzyme and non-coenzyme roles. A well-documented consequence of thiamine deficiency is reduced ACh synthesis (60), partly due to the direct role of pyruvate dehydrogenase in supplying acetyl-CoA, the essential precursor for ACh. Additionally, the distribution of acetyl-CoA and its supply for ACh synthesis is also governed by KGDH through its regulation of the TCA cycle, which further links thiamine homeostasis with cholinergic function. However, beyond its metabolic role as a coenzyme, thiamine is essential for axonal membrane excitability and neuronal action potentials (85). Phosphorylated thiamine derivatives regulate ACh neurotransmission (86) and are involved in synaptic function (87,88). Synaptic co-release of thiamine and ACh, with thiamine facilitating neurotransmission, has also been found (89-92). At high concentration, thiamine binds to nicotine ACh receptors (93), while the synthetic thiamine derivatives TTFD and sulbutiamine demonstrate pro-cholinergic effects in multiple studies (94,95). Given these diverse mechanisms, thiamine likely exerts its neuroprotective action through a combination of coenzyme and non-coenzyme effects, further cementing its role as a promising candidate for supporting neurodegenerative states which involve cholinergic decline.Huntington's Disease
Inhibition of pyruvate dehydrogenase (96,97) and KGDH (98) have been found. A decrease in thiamine content of the cerebrospinal fluid was shown to precede the onset of motor symptoms (99). Abnormal thiamine metabolism has been found in HD animal models (100), and a recent study identified impaired thiamine transport as a potentially treatable cause of HD. More specifically, abberant polyadenylation of thiamine transporters (SLC19A3) were identified in HD, accompanied by low striatal content of active thiamine in both humans and animals. Supplementation with high dose thiamine combined with biotin improved radiological, motor and neuropathological phenotypes in the animal model (101), and human studies are currently underway (102).Amyotrophic Lateral Sclerosis
The frontal cortext in ALS displays substantially lower levels of TPPase, the enzyme which activates thiamine to thiamine pyrophosphate (103), and patients exhibit decreased thiamine derivatives in the cerebrospinal fluid (104). The morphological signatures of Wernicke Encephalopathy have been reported in ALS (105). A case study using high dose benfotiamine (a thiamine derivative) showed promising results in ALS patient (106). Likewise, high doses of another derivative named dibenzoylthiamine normalized the metabolome and lead to improvements in all physiological parameters, motor function and muscle atrophy in an animal model of ALS (107). A series of case reports by Dr Antonio Costantini showed positive responses to high-dose thiamine (HDT) treatment in various other neurological conditions such as dystonia and spinocerebellar ataxia (108), along with a case report on fibromyalgia which showed up to 70% improvement in fatigue and 80% reduction in pain scores (109). Such findings could potentially be explained by dysfunctional thiamine utilization reported in this condition, evidenced by a significantly elevated TPP effect for transketolase (110), and low TPP levels (111), along with low thiamine binding affinity was observed for PDH (112) and transketolase (113).
Collectively, these findings suggest that dysfunction of thiamine-dependent enzymes and/or defects in thiamine metabolism, utilization, or transport may extend far beyond conventional associations, playing a significant role in the pathophysiology of diseases which not traditionally associated with TD.